Shopping Cart 0
Cart Subtotal
USD 0

Real World Evidence Market: Market Segments: By Component (Claims Data, Clinical Settings Data, Patient-Powered Data, Pharmacy Data and Others); By End User (Healthcare Payers, Healthcare Providers, Pharmaceutical & Medical Device Companies and Others); By Therapeutic Area (Oncology, Immunology, Neurology, Cardiovascular Disease and Others) and Region – Global Analysis of Market Size, Share & Trends for 2014 – 2020 and Forecasts to 2030

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option : NO
Copy Option : No
Download Option: No
Deliverable Format : Excel viewable on the website via username

Excel Only
USD 3000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 7500

Details

Product Overview

Real-world data is derived from various sources associated with the outcomes of the heterogeneous population of patients in real-world settings. It is the clinical confirmation regarding the consumption and potential risks or benefits of a medical product. Real-world data sets are extensively used for various applications such as market access & reimbursement/ coverage decisions, drug development & approvals, medical device development & approvals and clinical decision-making for real-world evidence which aids in the growth of the overall market. Real-world evidence (RWE) provides clear insight on possible treatment options that function in a wide population in comparison with a few patient pools in clinical trials. RWE insights are important in improving the efficiency of the cost of clinical trials and innovation, drug development and life cycle management.

Market Highlights

Global Real World Evidence Market is expected to project a notable CAGR of 15.95% in 2030.

Global Real World Evidence Market to surpass USD 4.74 billion by 2030 from USD 1.11 billion in 2020 at a CAGR of 15.95% in the coming years, i.e., 2020-30.  RWE market is growing due to rising geriatric population, a shift in value to the volume-based, mounting prevalence of chronic diseases, delays in drug development, and the subsequent increase in development costs which can be improved with the usage of real-world data sets that work as clinical evidence and recognized as efficient solutions by various pharmaceutical companies

Global Real World Evidence Market: Segments

Oncology segment to grow with the highest CAGR during 2020-30

Global Real World Evidence Market is segmented by therapeutic area into Oncology, Immunology, Neurology, Cardiovascular Disease, and Others. The oncology segment held the largest market share of XX.X% in the year 2019 owing to the rising prevalence of cancer across the globe and the conduct of a significant number of clinical oncology trials.

Pharmaceutical & medical device companies’ segment to grow with the highest CAGR during 2020-30

Global Real World Evidence Market is divided by end-user into Healthcare Payers, Healthcare Providers, Pharmaceutical & Medical Device Companies, and Others. The Pharmaceutical & Medical Device Companies segment held the largest market share of XX.X% in the year 2019 and will continue to dominate the market in the coming years. This is due to the rising importance of RWE studies for the approval and development of drugs, the requirement to prevent costly drug recalls, to assess the performance of drugs in real-world settings, and mounting emphasis on post-market surveillance and drug safety.

Market Dynamics

Drivers

Delayed drug development and high development costs

Development of a new pharmaceutical drug is of high risk with fewer chances for a successful outcome, time-consuming, and extremely costly. Healthcare and research organizations confront challenges posed by high costs and lengthy timelines to deliver medicines due to the hike in the emergence of rare diseases and growing inclination towards personalized healthcare.  Many companies seek possible ways to cut down the cost of clinical trials and evade barriers to escalate the drug development process.

Digitalization

Mounting use of mobile devices, computers, wearables, and other biosensors to accumulate and store a large volume of health-related data has been rapidly proliferating. Clinical trials in the health care setting can be conducted and properly planned with the help of the gathered data. Besides, with the development of new analytical capabilities, the data is analyzed and the results are applied to the medical product development and approval. Real-world evidence can be derived by the analysis of the real-world data gathered from various sources which are anticipated to drive the global market in the future years.

Restraint

Stringent government regulations

Strict government regulations and policies impede the growth of the global market since the manufacturers are required to obtain permits, licenses, product registrations, and other regulatory approvals to fulfill the security and operating standards of various government bodies. Also, the lack of a universally accepted standard for data collection and reluctance to depend upon real-world studies is expected to limit the growth of the global market.

Global Real World Evidence Market: Key Players

  • IQVIA

Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

  • IBM Corporation
  • Cognizant
  • Oracle Corporation
  • Syneos Health
  • Pharmaceutical Product Development
  • Clinigen Group plc
  • PAREXEL International Corporation
  • Palantir Technologies
  • SAS
  • Other Prominent Players

Global Real World Evidence Market: Regions

Global Real World Evidence Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Global Real World Evidence Market in North America held the largest market share of XX.X% in the year 2019. North America will continue to dominate the global Real World Evidence Market due to the presence of a well-established pharmaceutical industry, favorable regulatory environment, persistent expenditure in research & development activities which is projected to boost the market in this region.

    Global Real World Evidence Market is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada

  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America

  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
  • Asia Pacific (APAC) Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
  • Middle East and Africa (MEA) Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MEA

Global Real World Evidence Market report also contains analysis on:

Real-World Evidence Market Segments:

  • By Component
    • Claims Data
    • Clinical Settings Data
    • Patient-Powered Data
    • Pharmacy Data
    • Others
  • By End-User
    • Healthcare Payers
    • Healthcare Providers
    • Pharmaceutical & Medical Device Companies
    • Others
  • By Therapeutic Area
    • Oncology
    • Immunology
    • Neurology
    • Cardiovascular Disease
    • Others
  • Real-World Evidence Market Dynamics
  • Real-World Evidence Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies Involved in the Market
  • Value Chain of the Market
  • Market Drivers and Restraints
READ MORE

Table Of Content

Scope

Contents          

  1. Executive Summary
  2. Global Real World Evidence Market
    1. Product Overview
    2. Market Definition
    3. Segmentation
    4. Assumptions and Acronyms
  3. Research Methodology
    1. Research Objectives
    2. Primary Research
    3. Secondary Research
    4. Forecast Model
    5. Market Size Estimation
  4. Average Pricing Analysis
  5. Macro-Economic Indicators
  6. Market Dynamics
    1. Growth Drivers
    2. Restraints
    3. Opportunity
    4. Trends
  7. Correlation & Regression Analysis
    1. Correlation Matrix
    2. Regression Matrix
  8. Recent Development, Policies & Regulatory Landscape
  9. Risk Analysis
    1. Demand Risk Analysis
    2. Supply Risk Analysis
  10. Global Real World Evidence Analysis
    1. Porters Five Forces
      1. Threat of New Entrants
      2. Bargaining Power of Suppliers
      3. Threat of Substitutes
      4. Rivalry
    2. PEST Analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
  11. Global Real World Evidence Market
    1. Market Size & forecast, 2020A-2030F
      1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12. Global Real-World Evidence: Market Segmentation
    1. By Regions
      1. North America:(U.S. and Canada) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
    2. By Component: Market Share (2020-2030F)
      1. Claims Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      2. Clinical Settings Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      3. Patient-Powered Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      4. Pharmacy Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      5. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
    3. By End-User: Market Share (2020-2030F)
      1. Healthcare Providers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2020-2030
      2. Pharmaceutical & Medical Device Companies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      3. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
    4. By Therapeutic Area: Market Share (2020-2030F)
      1. Oncology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      2. Immunology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      3. Neurology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      4. Cardiovascular Disease, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      5. Other Solutions, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

13.  Company Profile

  1. IQVIA
    1. Company Overview
    2. Company Total Revenue (Financials)
    3. Market Potential
    4. Global Presence
    5. Key Performance Indicators
    6. SWOT Analysis
    7. Product Launch
  2. IBM Corporation
  3. Cognizant
  4. Oracle Corporation
  5. Syneos Health
  6. Pharmaceutical Product Development
  7. Clinigen Group plc
  8. PAREXEL International Corporation
  9. Palantir Technologies
  10. SAS
  11. Other Prominent Players

Consultant Recommendation

**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

Licence Rights

  • Single User License:

    Access to the soft copy of the report will be granted to individual user/ Authorized User within the organization. The Authorized User may store, display or archive the information but will not be able to print, copy and use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete/part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. The report will be MAC address protected and will only be accessible on 1 platform.

  •  
  • Hard Copy License:

    The license provides the access to hard copy/ printed copy of the report to the Authorized User only. The report will be delivered to the user on the address provided during making the purchase. The Authorized User may store, display, or archive the information but will not use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. No soft copy access will be provided in this case.

  •  
  • Corporate User License:

    Access to the soft copy of the report will be granted to multiple users within the organization. The users are authorized to store, display, duplicate, archive, print and distribute the information within the organization either electronically or in paper. The users are not authorized to use any information in the report for citation and circulation externally. The users will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Product Overview

Real-world data is derived from various sources associated with the outcomes of the heterogeneous population of patients in real-world settings. It is the clinical confirmation regarding the consumption and potential risks or benefits of a medical product. Real-world data sets are extensively used for various applications such as market access & reimbursement/ coverage decisions, drug development & approvals, medical device development & approvals and clinical decision-making for real-world evidence which aids in the growth of the overall market. Real-world evidence (RWE) provides clear insight on possible treatment options that function in a wide population in comparison with a few patient pools in clinical trials. RWE insights are important in improving the efficiency of the cost of clinical trials and innovation, drug development and life cycle management.

Market Highlights

Global Real World Evidence Market is expected to project a notable CAGR of 15.95% in 2030.

Global Real World Evidence Market to surpass USD 4.74 billion by 2030 from USD 1.11 billion in 2020 at a CAGR of 15.95% in the coming years, i.e., 2020-30.  RWE market is growing due to rising geriatric population, a shift in value to the volume-based, mounting prevalence of chronic diseases, delays in drug development, and the subsequent increase in development costs which can be improved with the usage of real-world data sets that work as clinical evidence and recognized as efficient solutions by various pharmaceutical companies

Global Real World Evidence Market: Segments

Oncology segment to grow with the highest CAGR during 2020-30

Global Real World Evidence Market is segmented by therapeutic area into Oncology, Immunology, Neurology, Cardiovascular Disease, and Others. The oncology segment held the largest market share of XX.X% in the year 2019 owing to the rising prevalence of cancer across the globe and the conduct of a significant number of clinical oncology trials.

Pharmaceutical & medical device companies’ segment to grow with the highest CAGR during 2020-30

Global Real World Evidence Market is divided by end-user into Healthcare Payers, Healthcare Providers, Pharmaceutical & Medical Device Companies, and Others. The Pharmaceutical & Medical Device Companies segment held the largest market share of XX.X% in the year 2019 and will continue to dominate the market in the coming years. This is due to the rising importance of RWE studies for the approval and development of drugs, the requirement to prevent costly drug recalls, to assess the performance of drugs in real-world settings, and mounting emphasis on post-market surveillance and drug safety.

Market Dynamics

Drivers

Delayed drug development and high development costs

Development of a new pharmaceutical drug is of high risk with fewer chances for a successful outcome, time-consuming, and extremely costly. Healthcare and research organizations confront challenges posed by high costs and lengthy timelines to deliver medicines due to the hike in the emergence of rare diseases and growing inclination towards personalized healthcare.  Many companies seek possible ways to cut down the cost of clinical trials and evade barriers to escalate the drug development process.

Digitalization

Mounting use of mobile devices, computers, wearables, and other biosensors to accumulate and store a large volume of health-related data has been rapidly proliferating. Clinical trials in the health care setting can be conducted and properly planned with the help of the gathered data. Besides, with the development of new analytical capabilities, the data is analyzed and the results are applied to the medical product development and approval. Real-world evidence can be derived by the analysis of the real-world data gathered from various sources which are anticipated to drive the global market in the future years.

Restraint

Stringent government regulations

Strict government regulations and policies impede the growth of the global market since the manufacturers are required to obtain permits, licenses, product registrations, and other regulatory approvals to fulfill the security and operating standards of various government bodies. Also, the lack of a universally accepted standard for data collection and reluctance to depend upon real-world studies is expected to limit the growth of the global market.

Global Real World Evidence Market: Key Players

  • IQVIA

Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

  • IBM Corporation
  • Cognizant
  • Oracle Corporation
  • Syneos Health
  • Pharmaceutical Product Development
  • Clinigen Group plc
  • PAREXEL International Corporation
  • Palantir Technologies
  • SAS
  • Other Prominent Players

Global Real World Evidence Market: Regions

Global Real World Evidence Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Global Real World Evidence Market in North America held the largest market share of XX.X% in the year 2019. North America will continue to dominate the global Real World Evidence Market due to the presence of a well-established pharmaceutical industry, favorable regulatory environment, persistent expenditure in research & development activities which is projected to boost the market in this region.

    Global Real World Evidence Market is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada

  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America

  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
  • Asia Pacific (APAC) Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
  • Middle East and Africa (MEA) Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MEA

Global Real World Evidence Market report also contains analysis on:

Real-World Evidence Market Segments:

  • By Component
    • Claims Data
    • Clinical Settings Data
    • Patient-Powered Data
    • Pharmacy Data
    • Others
  • By End-User
    • Healthcare Payers
    • Healthcare Providers
    • Pharmaceutical & Medical Device Companies
    • Others
  • By Therapeutic Area
    • Oncology
    • Immunology
    • Neurology
    • Cardiovascular Disease
    • Others
  • Real-World Evidence Market Dynamics
  • Real-World Evidence Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies Involved in the Market
  • Value Chain of the Market
  • Market Drivers and Restraints
READ MORE

Scope

Contents          

  1. Executive Summary
  2. Global Real World Evidence Market
    1. Product Overview
    2. Market Definition
    3. Segmentation
    4. Assumptions and Acronyms
  3. Research Methodology
    1. Research Objectives
    2. Primary Research
    3. Secondary Research
    4. Forecast Model
    5. Market Size Estimation
  4. Average Pricing Analysis
  5. Macro-Economic Indicators
  6. Market Dynamics
    1. Growth Drivers
    2. Restraints
    3. Opportunity
    4. Trends
  7. Correlation & Regression Analysis
    1. Correlation Matrix
    2. Regression Matrix
  8. Recent Development, Policies & Regulatory Landscape
  9. Risk Analysis
    1. Demand Risk Analysis
    2. Supply Risk Analysis
  10. Global Real World Evidence Analysis
    1. Porters Five Forces
      1. Threat of New Entrants
      2. Bargaining Power of Suppliers
      3. Threat of Substitutes
      4. Rivalry
    2. PEST Analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
  11. Global Real World Evidence Market
    1. Market Size & forecast, 2020A-2030F
      1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
  12. Global Real-World Evidence: Market Segmentation
    1. By Regions
      1. North America:(U.S. and Canada) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
    2. By Component: Market Share (2020-2030F)
      1. Claims Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      2. Clinical Settings Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      3. Patient-Powered Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      4. Pharmacy Data, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      5. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
    3. By End-User: Market Share (2020-2030F)
      1. Healthcare Providers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2020-2030
      2. Pharmaceutical & Medical Device Companies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      3. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
    4. By Therapeutic Area: Market Share (2020-2030F)
      1. Oncology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      2. Immunology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      3. Neurology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      4. Cardiovascular Disease, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
      5. Other Solutions, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

13.  Company Profile

  1. IQVIA
    1. Company Overview
    2. Company Total Revenue (Financials)
    3. Market Potential
    4. Global Presence
    5. Key Performance Indicators
    6. SWOT Analysis
    7. Product Launch
  2. IBM Corporation
  3. Cognizant
  4. Oracle Corporation
  5. Syneos Health
  6. Pharmaceutical Product Development
  7. Clinigen Group plc
  8. PAREXEL International Corporation
  9. Palantir Technologies
  10. SAS
  11. Other Prominent Players

Consultant Recommendation

**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

  • Single User License:

    Access to the soft copy of the report will be granted to individual user/ Authorized User within the organization. The Authorized User may store, display or archive the information but will not be able to print, copy and use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete/part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. The report will be MAC address protected and will only be accessible on 1 platform.

  •  
  • Hard Copy License:

    The license provides the access to hard copy/ printed copy of the report to the Authorized User only. The report will be delivered to the user on the address provided during making the purchase. The Authorized User may store, display, or archive the information but will not use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. No soft copy access will be provided in this case.

  •  
  • Corporate User License:

    Access to the soft copy of the report will be granted to multiple users within the organization. The users are authorized to store, display, duplicate, archive, print and distribute the information within the organization either electronically or in paper. The users are not authorized to use any information in the report for citation and circulation externally. The users will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS